Payment overview · 2025
General Payments
$455.22
20 reported records · 13 companies
Healthcare provider profile · identity verified
William Crawford, MD
Allopathic & Osteopathic Physicians|Family Medicine · HAVELOCK, NC · NPI 1730117110
Verified facts
What the public records show
CMS Open Payments records show William Crawford, MD received $455.22 in general payments during 2025 across 20 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 21.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $96.98 | 21.3% | 4 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $79.53 | 17.5% | 1 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $52.04 | 11.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $48.64 | 10.7% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $36.79 | 8.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $27.69 | 6.1% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $23.62 | 5.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.61 | 3.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.13 | 3.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.80 | 3.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.59 | 3.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.07 | 3.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.73 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $455.22 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $96.98 | 4 | 2025 |
Source payment records
|
|||||
| Hillrom - Cardiac Ambulatory Monitor Normalized: hillrom cardiac ambulatory monitor |
Device | Baxter Healthcare | $79.53 | 1 | 2025 |
Source payment records
|
|||||
| UROLIFT Normalized: urolift |
Device | Teleflex LLC | $52.04 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $48.64 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.35 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $27.69 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $27.69 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $23.62 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.13 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.80 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.59 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.07 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.73 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $13.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 80 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
80 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
80 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
48 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
97 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
31 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 406 | 129 |
| Lisinopril | Lisinopril | 284 | 83 |
| Gabapentin | Gabapentin | 253 | 65 |
| Losartan Potassium | Losartan Potassium | 237 | 71 |
| Omeprazole | Omeprazole | 229 | 67 |
| Levothyroxine Sodium | Levothyroxine Sodium | 223 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 210 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 170 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 168 | 52 |
| Furosemide | Furosemide | 153 | 47 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 148 | 41 |
| Prednisone | Prednisone | 148 | 82 |
| Ibuprofen | Ibuprofen | 133 | 36 |
| Potassium Chloride | Potassium Chloride | 133 | 40 |
| Metformin Hcl | Metformin Hcl | 131 | 36 |
| Montelukast Sodium | Montelukast Sodium | 127 | 32 |
| Doxycycline Hyclate | Doxycycline Hyclate | 124 | 69 |
| Alprazolam | Alprazolam | 120 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 117 | 44 |
| Sertraline Hcl | Sertraline Hcl | 111 | 32 |
| Tramadol Hcl | Tramadol Hcl | 111 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 109 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 108 | 25 |
| Lorazepam | Lorazepam | 98 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 98 | 36 |
| Eliquis | Apixaban | 97 | 21 |
| Trazodone Hcl | Trazodone Hcl | 97 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 95 | 36 |
| Celecoxib | Celecoxib | 92 | 28 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 91 | 72 |
| Cephalexin | Cephalexin | 85 | 58 |
| Oxycodone Hcl | Oxycodone Hcl | 85 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 84 | 18 |
| Jardiance | Empagliflozin | 80 | 14 |
| Simvastatin | Simvastatin | 71 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 70 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 68 | 14 |
| Fluconazole | Fluconazole | 66 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 62 | 13 |
| Meloxicam | Meloxicam | 62 | 19 |
| Clonidine Hcl | Clonidine Hcl | 60 | 15 |
| Allopurinol | Allopurinol | 59 | 18 |
| Pregabalin | Pregabalin | 58 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 56 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 56 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 53 | 17 |
| Carvedilol | Carvedilol | 51 | 14 |
| Ezetimibe | Ezetimibe | 51 | 14 |
| Mounjaro | Tirzepatide | 50 | suppressed |
| Clonazepam | Clonazepam | 49 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 48 | suppressed |
| Ozempic | Semaglutide | 48 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 12 |
| Mirtazapine | Mirtazapine | 45 | suppressed |
| Azithromycin | Azithromycin | 43 | 37 |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | suppressed |
| Synthroid | Levothyroxine Sodium | 42 | suppressed |
| Temazepam | Temazepam | 41 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 41 | 20 |
| Meclizine Hcl | Meclizine Hcl | 40 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 38 | suppressed |
| Ondansetron Odt | Ondansetron | 37 | 22 |
| Donepezil Hcl | Donepezil Hcl | 36 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 35 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 33 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 33 | 17 |
| Metformin Hcl Er | Metformin Hcl | 33 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 31 | 30 |
| Trulicity | Dulaglutide | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 14 |
| Dilt-Xr | Diltiazem Hcl | 29 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Cefdinir | Cefdinir | 28 | 17 |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 27 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Famotidine | Famotidine | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Colchicine | Colchicine | 19 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Ibu | Ibuprofen | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Minoxidil | Minoxidil | 14 | suppressed |
| Moxifloxacin Hcl | Moxifloxacin Hcl | 14 | 14 |
| Tolterodine Tartrate | Tolterodine Tartrate | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Desloratadine | Desloratadine | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Mercaptopurine | Mercaptopurine | 11 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $455.22 · 20 records | Bayer Healthcare Pharmaceuticals Inc. | AREXVY, Cologuard Collection Kit, Dexcom G6 Transmitter, Hillrom - Cardiac Ambulatory Monitor, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, REPATHA, UROLIFT, VOQUEZNA, XIFAXAN, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error